Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-17
2007-04-17
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S105000
Reexamination Certificate
active
10730680
ABSTRACT:
The present invention provides compounds of Formula Iwherein W, Q, E, D, R6, R7, R8, Y, K, R9, R10, R12, G, and the double bond denoted “*” have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
REFERENCES:
patent: 4824833 (1989-04-01), Iijima et al.
patent: 5703075 (1997-12-01), Gammill et al.
patent: 6355664 (2002-03-01), Boehringer
patent: 6518277 (2003-02-01), Sadhu et al.
patent: 2004/0092561 (2004-05-01), Ruckle et al.
patent: 1277738 (2003-01-01), None
patent: WO 00/76987 (2000-12-01), None
patent: WO 00/76988 (2000-12-01), None
patent: WO 01/53266 (2001-07-01), None
patent: WO 01/81346 (2001-11-01), None
patent: WO 04/007491 (2004-01-01), None
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996).
Abstract of US20040092561A1 (STN printout) 2 pages.
Chemical Abstract AN: 2003:1957877 CHEMCATS, PD: Jul. 9, 2002.
Chemical Abstract AN: 2003:1940777 CHEMCATS, PD: Jul. 9, 2002.
Chemical Abstract AN: 2003:1940509 CHEMCATS, PD: Jul. 9, 2002.
Chemical Abstract AN: 2003:1940371 CHEMCATS, PD: Jul. 9, 2002.
Chemical Abstract AN: 2002:2995642 CHEMCATS, PD: Jan. 17, 2002.
Chemical Abstract AN: 2002:2977312 CHEMCATS, PD: Jul. 9, 2002.
Chemical Abstract AN: 2002:2647933 CHEMCATS, PD: Jul. 9, 2002.
Chemical Abstract AN: 2002:2272781 CHEMCATS, PD: Jul. 9, 2002.
Chemical Abstract AN: 2002:1467769 CHEMCATS, PD: Jan. 17, 2002.
Chemical Abstract AN: 2002:1464450 CHEMCATS, PD: Jan. 17, 2002.
Chemical Abstract AN: 2002:1461688 CHEMCATS, PD: Jan. 17, 2002.
Chemical Abstract AN: 2002:1460415 CHEMCATS, PD: Jan. 17, 2002.
Chemical Abstract AN: 2002:1458784 CHEMCATS, PD: Jan. 17, 2002.
Chemical Abstract AN: 2002:1455387 CHEMCATS, PD: Jan. 17, 2002.
Alimov, et al., Somatic Mutation and Homozygous Deletion fo PTEN/MMACI Gene 10q23 in Renal Cell Carcinoma, Anticancer Research, 1999, pp. 3841-3846, vol. 19.
Borlando, et al., Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo, FASEB J., May 2000, pp. 895-903, vol. 14.
Brass, et al., DNA Amplification on Chromosome 3q26.1-q26.3 in Squamous Cell Carcinoma of the Lung Detected by Reverse Chromosome Painting, Eur. J. Cancer, 1996, pp. 1205-1208, vol. 32A(7), Great Briatin.
Forgacs, et al., Mutation analysis of the PTEN/MMAC1 gene in lung cancer, Oncogene, 1998, pp. 1557-1565, vol. 17.
Hirsch, et al., Central Role for G Protein-Coupled Phosphoinositide 3-Kinase in Inflammation, Science, Feb. 2000, pp. 1049-1053, vol. 287, USA.
Hirsch, et al., Resistance to thromboemolism in PI3K-deficient mice, FASEB Journal, Jul. 2001, pp. 2019-2021, USA.
Hu, et al., Inhibition of Phosphatidylinositol, 3′-Kinase Increases Efficancy of Pactitaxel in in Vitro and in Vivo Ovarian Cancer Models I, Cancer Res., Feb. 2002, pp. 1087-1092, vol. 62.
Jimenez, et al., Identification and characterization of new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase, EMBO Journal, 1998, pp. 743-753, vol. 17(3), USA.
Katso, et al., Cellular Function of phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer, Annu. Rev. Cell Dev. Biol. 2001, pp. 615-675, vol. 17, USA.
Kotelevets, et al., Inhibition by Platelet-activating Factor of Src-and Hepatocyte Growth Factor-dependent Invasiveness of Intestinal and Kidney Epithelial Cells, J. Biol. Chem., Jun. 1998, pp. 14138-14145, vol. 273(23), USA.
Krchak, et al., A solid phase traceless synthesis of quinoxalinones, Tetrahedron Letters, 2000, pp. 2835-2838, USA.
Lee, et al., Solid-phase combinatorial synthesis of 5-arylalkylidene rhodanine, Tetrahedron Letters, 2000, pp. 5729-5732, USA.
Lee, et al., The Raf/MEK/ERK singal transduction cascade as a targe for chemotherapeutic intervention in leuikemia, Leukemia, 2002, pp. 486-507, vol. 16, USA.
Leopoldt, et al., GBY Stimulates Phosphoinositide 3-Kinasey-y by Direct Interaction with Two Domains of the Catalytic p110 Subunit, Dec. 1997, pp. 7024-7029, vol. 273(12), USA.
Ma, et al., PIK3CA as an oncogene in cervical cancer, Oncogene, 2000 pp. 2739-2744, vol. 19.
Nakanishi, et al., Novel Functions of Phosphatidylinositol 3-Kinase in Terminally Differentiated Cells, Cellular Signalling, 1995, pp. 545-557, vol. 6, Great Britain.
Philp, et al., The Phosphatidylinositol 3′-kinase p85a Gene Is an Oncogene in Human Ovarian and Colon Tumors1, Cancer Sesearch, Oct. 2001, pp. 7426-7429, vol. 61, USA.
Shayesteh, et al., PIK3CA is implicated as an oncogene in ovarian cancer, Nature Genetics, Jan. 1999, pp. 99-102, vol. 21.
Susa, et al., Platelet-derived Growth Factor Activates Membrane-associated Phosphatidylinositol 3-Kinase and Mediates Its Translocation from the Cytosol, Nov. 1992. pp. 22951-22956, vol. 267(32), USA.
Vanhaesebroeck, et al., p110, a novel phosphoinositide 3-kinase in leukocytes, Proc. Natl. Acad. Sci., Apr. 1997, pp. 4330-4335, vol. 94, USA.
Vivanco, et al., The Phosphatidylinositol 3-Kinase-Art Pathway in Human Cancer, Nature Reviews Cancer, Jul. 2002, pp. 489-501, vol. 2, USA.
Barvian Nicole
Kolz Christine Nylund
Para Kimberly Suzanne
Patt William Chester
Visnick Melean
Habte Kahsay
Warner-Lambert Company LLC
Yakovleva Galina M.
Zielinski Bryan C.
LandOfFree
Benzoxazin-3-ones and derivatives thereof as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzoxazin-3-ones and derivatives thereof as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoxazin-3-ones and derivatives thereof as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3743764